News
TriSalus Life Sciences Q4 2023 GAAP EPS $(1.56) Misses $(0.69) Estimate, Sales $5.721M Beat $5.453M Estimate
1 Apr 24
Earnings, Earnings Beats, Earnings Misses, News
Earnings Scheduled For April 1, 2024
1 Apr 24
Earnings
TriSalus Life Sciences Expects Sales To Grow In Excess Of 50% In 2024; Says Currently In The Process Of Obtaining Additional Liquidity To Fund Operations Through 2024
11 Mar 24
News, Guidance
TriSalus Life Sciences Reports Preliminary Q4 Sales Of Approximately $5.7M, Representing 77% Growth Versus 2022; Est $5.453M
11 Mar 24
News, Guidance
Press releases
TriSalus Life Sciences Technology Featured in Two Presentations at the Society of Interventional Radiology Annual Scientific Meeting
26 Mar 24
Press Releases
TriSalus Life Sciences Announces Q4 Conference Call and Preliminary and Unaudited Q4 and Full Year 2023 Financial Results
11 Mar 24
Press Releases
TriSalus Life Sciences Receives Approval from the World Health Organization and the American Medical Association's Adopted Name Council for "Nelitolimod" as the Nonproprietary Drug Name for SD-101
7 Mar 24
Press Releases
ORI Capital Raises $260 Million for Second Life Sciences Fund
22 Feb 24
Press Releases